CN117298142B - Composition for resisting asthenopia and preparation method and application thereof - Google Patents
Composition for resisting asthenopia and preparation method and application thereof Download PDFInfo
- Publication number
- CN117298142B CN117298142B CN202311598876.6A CN202311598876A CN117298142B CN 117298142 B CN117298142 B CN 117298142B CN 202311598876 A CN202311598876 A CN 202311598876A CN 117298142 B CN117298142 B CN 117298142B
- Authority
- CN
- China
- Prior art keywords
- parts
- ophiopogon
- asthenopia
- paeoniflorin
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims description 38
- 229930195210 Ophiopogon Natural products 0.000 claims description 30
- 150000004676 glycans Chemical class 0.000 claims description 21
- 229920001282 polysaccharide Polymers 0.000 claims description 21
- 239000005017 polysaccharide Substances 0.000 claims description 21
- FBSFWRHWHYMIOG-UHFFFAOYSA-N methyl 3,4,5-trihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=C(O)C(O)=C1 FBSFWRHWHYMIOG-UHFFFAOYSA-N 0.000 claims description 20
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 19
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 16
- 244000182216 Mimusops elengi Species 0.000 claims description 16
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 16
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 16
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 14
- 229960000306 zinc gluconate Drugs 0.000 claims description 14
- 235000011478 zinc gluconate Nutrition 0.000 claims description 14
- 239000011670 zinc gluconate Substances 0.000 claims description 14
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 12
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 12
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 12
- 235000009498 luteolin Nutrition 0.000 claims description 12
- IFJUVMQPFHUIKX-UHFFFAOYSA-N Saponin D Natural products CC1CCC2(OC1)OC3CC4C5CCC6CC(CCC6(C)C5CC(=O)C4(C)C3C2C)OC7OC(CO)C(OC8OC(CO)C(OC9OC(CO)C(OC%10OC(C)C(O)C(O)C%10O)C(O)C9OC%11OC(O)C(O)CC%11O)C(O)C8O)C(O)C7O IFJUVMQPFHUIKX-UHFFFAOYSA-N 0.000 claims description 11
- FJESIUXDUUJRCG-UHFFFAOYSA-N Saponin D Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(C3C(C4C(C56CC7(C(C(CC(O7)C=C(C)C)(C)OC7C(C(O)C(O)C(C)O7)O)C6CC4)OC5)(C)CC3)(C)CC2)(C)C)OC(CO)C(O)C1O FJESIUXDUUJRCG-UHFFFAOYSA-N 0.000 claims description 11
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 10
- XXDBCABHQMLKHQ-UHFFFAOYSA-N 2-methyl-2-phenyl-3h-chromen-4-one Chemical compound C1C(=O)C2=CC=CC=C2OC1(C)C1=CC=CC=C1 XXDBCABHQMLKHQ-UHFFFAOYSA-N 0.000 claims description 10
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 10
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 10
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 claims description 10
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 10
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 10
- 235000005487 catechin Nutrition 0.000 claims description 10
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 10
- 229940074393 chlorogenic acid Drugs 0.000 claims description 10
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 10
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 10
- 229950001002 cianidanol Drugs 0.000 claims description 10
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 10
- 229940116852 myricetin Drugs 0.000 claims description 10
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 claims description 10
- 235000007743 myricetin Nutrition 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- IBKQQKPQRYUGBJ-UHFFFAOYSA-N methyl gallate Natural products CC(=O)C1=CC(O)=C(O)C(O)=C1 IBKQQKPQRYUGBJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 244000241838 Lycium barbarum Species 0.000 claims description 2
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 2
- 235000015468 Lycium chinense Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 241001448424 Ophiopogon Species 0.000 claims 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 26
- 210000001508 eye Anatomy 0.000 abstract description 21
- 230000004438 eyesight Effects 0.000 abstract description 21
- 230000006378 damage Effects 0.000 abstract description 14
- 208000027418 Wounds and injury Diseases 0.000 abstract description 7
- 208000014674 injury Diseases 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 7
- 206010013774 Dry eye Diseases 0.000 abstract description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 45
- 229940079593 drug Drugs 0.000 description 23
- 244000248557 Ophiopogon japonicus Species 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000003078 antioxidant effect Effects 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 241000723353 Chrysanthemum Species 0.000 description 8
- 235000007516 Chrysanthemum Nutrition 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 238000005286 illumination Methods 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 102000016938 Catalase Human genes 0.000 description 7
- 108010053835 Catalase Proteins 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 210000000695 crystalline len Anatomy 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000005252 bulbus oculi Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000011160 research Methods 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 230000004382 visual function Effects 0.000 description 4
- QQUHMASGPODSIW-UHFFFAOYSA-N Albiflorin Natural products C=1C=CC=CC=1C(=O)OCC12C(=O)OC3(C)CC(O)C1CC32OC1OC(CO)C(O)C(O)C1O QQUHMASGPODSIW-UHFFFAOYSA-N 0.000 description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 description 3
- 241001106477 Paeoniaceae Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- QQUHMASGPODSIW-ICECTASOSA-N albiflorin Chemical compound O([C@@]12C[C@H]3[C@H](O)C[C@@]1(OC(=O)[C@]32COC(=O)C=1C=CC=CC=1)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QQUHMASGPODSIW-ICECTASOSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- -1 coatings Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 244000236658 Paeonia lactiflora Species 0.000 description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000008832 photodamage Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 235000016804 zinc Nutrition 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 230000004300 dark adaptation Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an anti-asthenopia composition, a preparation method and application thereof, belonging to the technical field of compositions, wherein the composition comprises the following active ingredients: the invention can effectively relieve symptoms such as dry eyes, unsmooth eyes, swelling feeling of eyes and the like caused by asthenopia, and can resist blue light irradiation injury, relieve asthenopia and protect eyesight. Compared with the commercial products, the invention has better protection effect on vision injury caused by blue light irradiation.
Description
Technical Field
The invention relates to the technical field of compositions, in particular to an anti-asthenopia composition, and a preparation method and application thereof.
Background
Eye health is also a constant pursuit of the national world, being one of the most important organs in the human sense. However, with the acceleration of modern society's learning, work tension and life rhythm, and the popularization and application of televisions and computers, the use of the internet and new media has rapidly increased, the time for human to use vision has been prolonged, the distance between objects to be seen has been relatively shortened and the natural environment has been worsened, in recent years, the number of people suffering from asthenopia has increased in geometric grade, and the age of asthenopia has tended to be younger and younger, so that the asthenopia has become one of the current clinical symptoms common to ophthalmology.
The asthenopia is also called eye fatigue syndrome, which is a syndrome of the mutual interweaving of organic factors and mental factors of eyes or whole body based on the subjective symptoms of eyes of patients, and belongs to the category of mental and physical medicine. Visual fatigue is usually manifested by discomfort or pain around eyeballs and eyesockets, fear of light, tearing, double vision, etc., and serious general symptoms such as nausea and vomiting, listlessness, sleepiness, hypomnesis, insomnia, etc.
Western medicine mainly aims at symptomatic treatment and corrective treatment of asthenopia, sedatives and neurotrophic agents are generally used, and beta receptor blockers are also used by local dripping. In addition, visual fatigue may be treated by surgery, prismatic correction or visual training. Although the method has a relatively positive curative effect, the method has a relatively prominent side effect, is relatively narrow in application range, and cannot meet the control requirement of asthenopia syndrome.
The theory of inducing resuscitation of liver in eyes in traditional Chinese medicine holds that the occurrence of the disease is mainly related to ametropia, improper eye use, excessive vision, poor constitution, excessive heart and mind consumption and the like, and the pathogenesis is also related to organs such as liver, heart, kidney and the like. The main pathogenesis includes liver fatigue, heart blood deficiency and kidney essence deficiency.
Liver strain: the first mentioned "liver fatigue" in the six-up seven-orifice diseases of the book written in Tang Dynasty Simiao, the person who has mentioned reading and gamble overfatigue in the book is called liver fatigue. In the miscellaneous diseases classification eye of Ming Dynasty medical literature, "medical entry: the patients with excessive reading and needling with pain of eyes are called liver strain. "in traditional Chinese medicine, it is recorded that liver orifices and liver blood loss are the aim, and excessive brain consumption can cause that eyes lack nourishment and cannot watch things for a long time, so that discomfort such as headache, dizziness, eye pain, eye dryness, eye distention and the like is caused.
Heart blood deficiency: the dialectical analysis of visual fatigue on heart and blood deficiency in traditional Chinese medicine is that long-term watching can lead to fatigue, qi consumption, blood injury, channel blockage, qi and blood deficiency, adverse pulse and malnutrition of eyes and orifices, so that the eyes and the eyes are tired for a long time. So there is a mental issue in the eyes due to the heart blood being sufficient.
Kidney meridian deficiency: the traditional Chinese medicine in China considers that the essence and blood consumption of the kidney is caused, the essence and blood deficiency is caused, the tendons are malnourished, the regulation is malfunctioned, and the eyes are malnourished, so that the eyes are tired.
The traditional Chinese medicine also has a plurality of methods in the aspect of preventing and treating asthenopia syndrome, and obtains better clinical effects, such as a periocular acupuncture point moxibusting method, an ultrasonic atomization external fumigation method, a meridian conditioning method, a traditional Chinese medicine hot compress bag, a traditional Chinese medicine hot compress combined internal drink and the like. The traditional Chinese medicine starts from the whole body condition, has characteristics and advantages in the aspect of preventing and treating asthenopia syndrome, but still has a plurality of problems such as long time consumption for medical staff to massage acupoints, heavy fatigue degree, expensive price and compliance deviation. Today, the life rhythm is continuously accelerated, the treatment course is long, and the treatment course is long, so that the treatment course is not friendly to young people. In addition, if skin diseases and skin allergy or damage occur at the massage part, adverse reactions to the thunder fire moxibustion are not applicable.
At present, the incidence rate of asthenopia is high, and a plurality of inconveniences are brought to patients, and the learning, working efficiency and life quality are directly influenced, so that people pay more attention to how to prevent, treat and recuperate the asthenopia. With the improvement of public health consciousness, related products for relieving visual fatigue are required to be vigorous, but the number of safe and effective products is very small. Therefore, developing health-care food with definite efficacy and safe eating for relieving asthenopia is also an important subject of the eye science and modern people.
The food element medlar chrysanthemum zinc gluconate tablet is a special health food for relieving visual fatigue, is commercially available at present, contains five components of medlar, chrysanthemum, dwarf lilyturf tuber, white paeony root and zinc gluconate, has the effects of nourishing liver and kidney, activating blood and improving eyesight, can quickly relieve visual fatigue, and can deeply relieve eye problems caused by liver blood deficiency by supplementing and nourishing combination, thereby having the effect of relieving various symptoms of visual fatigue and muscat. The four traditional Chinese medicine active ingredients of medlar, chrysanthemum, dwarf lilyturf tuber and white paeony root in the medlar, chrysanthemum and zinc gluconate tablet are subjected to intensive research, so that the composition with excellent effect and capable of effectively relieving visual fatigue is found, and the composition has very important significance.
Disclosure of Invention
In order to solve the technical problems, the invention provides an anti-asthenopia composition, and a preparation method and application thereof.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
in a first aspect, the present invention provides an anti-asthenopia composition comprising the following active ingredients: lycium barbarum polysaccharide, catechin, myricetin, luteolin, chlorogenic acid, ophiopogon polysaccharide, ophiopogon saponin D, ophiopogon methyl flavanone A, paeoniflorin, methyl gallate, albiflorin and zinc gluconate.
Medlar: has mild nature and sweet taste, and has effects of nourishing liver and kidney and improving eyesight. Modern medical research shows that the medlar has a protective effect on ganglion cells, and can slow down the vision degradation of patients suffering from retinal pigment degeneration; and (3) chrysanthemum: the tea is sweet, bitter and cool, has the effects of nourishing liver and kidney, suppressing hyperactive liver and subsiding yang, clearing liver and improving eyesight, and can be used for conditioning symptoms such as dim eyesight, blurred vision, and lacrimation caused by deficiency of liver and kidney and deficiency of essence and blood; white peony root: sweet, bitter and sour in taste, slightly cold in nature, entering liver and spleen meridians; has effects in nourishing blood, softening liver, relieving pain, astringing yin, and stopping sweat. Radix Ophiopogonis: sweet, slightly bitter and slightly cold. It is indicated for heart, lung and stomach meridians, nourishing yin, promoting fluid production, moistening lung and relieving cough. Has effects of clearing heart fire, moistening lung, nourishing yin, replenishing essence, clearing heat, relieving restlessness, eliminating phlegm, relieving cough, promoting salivation, and improving eyesight. Modern medical research shows that ophiopogon root has the function of dilating blood vessel. The active ingredients in medlar, chrysanthemum, white peony root and dwarf lilyturf tuber are carefully selected and compounded with zinc, and the obtained composition can play roles in resisting damage caused by blue light irradiation, relieving visual fatigue and protecting eyesight.
In some specific embodiments, the anti-asthenopia composition comprises the following active ingredients in parts by weight: 8-12 parts of medlar polysaccharide, 0.1-0.6 part of catechin, 0.2-1 part of myricetin, 0.4-1.5 part of luteolin, 1-2.5 parts of chlorogenic acid, 20-40 parts of ophiopogon polysaccharide, 0.02-0.08 part of ophiopogon saponin D, 0.01-0.05 part of ophiopogon methyl flavanone A, 5-13 parts of paeoniflorin, 0.2-0.8 part of gallic acid methyl ester, 1.8-3.6 parts of paeoniflorin and 80-120 parts of zinc gluconate.
In some specific embodiments, the anti-asthenopia composition comprises the following active ingredients in parts by weight: 9-11 parts of medlar polysaccharide, 0.2-0.5 part of catechin, 0.4-0.8 part of myricetin, 0.5-1.0 part of luteolin, 1.2-2.0 parts of chlorogenic acid, 22-38 parts of ophiopogon polysaccharide, 0.03-0.07 part of ophiopogon saponin D, 0.02-0.04 part of ophiopogon methyl flavanone A, 6-10 parts of paeoniflorin, 0.3-0.7 part of gallic acid methyl ester, 2.0-3.5 parts of paeoniflorin and 80-120 parts of zinc gluconate.
In some specific embodiments, the anti-asthenopia composition comprises the following active ingredients in parts by weight: 10 parts of medlar polysaccharide, 0.3 part of catechin, 0.6 part of myricetin, 0.7 part of luteolin, 1.5 parts of chlorogenic acid, 30 parts of ophiopogon polysaccharide, 0.04 part of ophiopogon saponin D, 0.04 part of ophiopogon methyl flavanone A, 9.5 parts of paeoniflorin, 0.5 part of gallic acid methyl ester, 2.6 parts of paeoniflorin and 100 parts of zinc gluconate.
In a second aspect, the invention also provides a method for preparing the composition.
The preparation method comprises the following steps: mixing the wolfberry polysaccharide, catechin, myricetin, luteolin, chlorogenic acid, ophiopogon polysaccharide, ophiopogon saponin D, ophiopogon methyl flavanone A, paeoniflorin, methyl gallate, paeoniflorin and zinc gluconate according to the formula amount, and sieving to obtain the composition.
Preferably, the sieving is through a 60-120 mesh sieve.
In a third aspect, the invention provides the use of the above composition for the preparation of an anti-asthenopia product.
The anti-asthenopia product is a medicine.
In a fourth aspect, the present invention provides an anti-asthenopia product comprising a composition.
The anti-asthenopia product can be tablets, capsules, granules, ointment, suspension, powder, injection, spray or pills.
The beneficial effects of the invention are as follows:
the composition is prepared by carefully selecting active ingredients in medlar, chrysanthemum, white paeony root and dwarf lilyturf tuber and zinc, can effectively relieve symptoms such as dry eyes, unsmooth eyes, swelling feeling of eyes and the like caused by asthenopia, can resist damage caused by blue light irradiation, can relieve asthenopia and can protect eyesight.
Experiments prove that compared with a commercial product, the invention has better protection effect on vision injury caused by blue light irradiation.
Detailed Description
The following examples are presented only to aid in understanding the method of the present invention and its core ideas. It should be noted that it will be apparent to those skilled in the art that various modifications and adaptations of the invention can be made without departing from the principles of the invention and these modifications and adaptations are intended to be within the scope of the invention as defined in the following claims. The following description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described herein.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The "compositions" and "anti-asthenopia products" described herein are generally compositions comprising a composition having a composition of several active ingredients (active ingredients for short) and pharmaceutically acceptable excipients, and in particular embodiments, the active ingredients described herein are provided in the composition in an effective amount (e.g., a therapeutically effective amount).
The "pharmaceutically acceptable auxiliary materials" in the present invention include inert diluents, dispersants and/or granulating agents, surfactants and/or emulsifying agents, disintegrants, binders, preservatives, buffers, lubricants and/or oils. Excipients, colorants, coatings, sweeteners, flavoring agents, and fragrances may also be present in the compositions.
The compositions of the present invention may be prepared by any method known in the art of pharmacy. Generally, these methods of preparation involve associating the active ingredient with a carrier or excipient and/or one or more other auxiliary ingredients, and then shaping and/or packaging the product into the desired single or multi-dose unit if needed and/or desired.
The composition of the present invention can be prepared according to a known method, for example, the method set forth in the general rules for the preparation of japanese pharmacopoeia (Japanese Pharmacopoeia) 16 th edition, united states pharmacopoeia (United States Pharmacopoeia) and european pharmacopoeia (European Pharmacopoeia) 9 th edition. Depending on the dosage form, the compositions of the present invention may be suitably administered to patients.
The active ingredients, adjuvants in the compositions herein will vary depending on the nature, size and/or condition of the subject being treated and further depending on the route of administration of the composition. The composition may comprise between 0.1% and 100% (w/w) active ingredient.
"treating" in the present invention means reversing, alleviating, inhibiting the progression of, or preventing the condition or disorder to which the term applies or one or more symptoms of such condition or disorder, unless indicated otherwise.
The active ingredients in this example are all common commercial products, and the purchase information is shown in Table 1.
TABLE 1 information on active ingredients
Example A composition for relieving asthenopia
The amounts of the active ingredients of the compositions are shown in Table 2.
Table 2 formulation of the compositions of examples and comparative examples
Among them, comparative example 1 is different from example 3 in that: the dosages of the medlar polysaccharide, the luteolin, the ophiopogon polysaccharide and the ophiopogon saponin D are different; comparative example 2 differs from example 3 in that: the dosages of the Lycium barbarum polysaccharide, the luteolin, the paeoniflorin and the albiflorin are different.
The preparation method of the composition comprises the following steps: mixing fructus Lycii polysaccharide, catechin, myricetin, luteolin, chlorogenic acid, radix Ophiopogonis polysaccharide, radix Ophiopogonis saponin D, radix Ophiopogonis methyl flavanone A, paeoniflorin, methyl gallate, albiflorin and zinc gluconate, and sieving with 80 mesh sieve.
Drug efficacy evaluation-study on protective Vision test
1. Experimental materials and drugs
1. Experimental animal
Male SD rats, body weight: 220-250g, grade: SPF stage. Animal production pass number purchased from vinca Yiss laboratory animal technology, inc.: SCXK (Ji) -2020-0002. The cultivation method is carried out in an environment with the temperature kept at (22+/-2) DEG C, the relative humidity of (60+/-2) percent and the illumination period of 12 hours.
2. Medicaments and agents
Experimental medicine: the compositions of examples 1-3 and comparative examples 1-2 were mixed to prepare experimental drugs, respectively, for use.
Positive drug: medlar chrysanthemum zinc gluconate tablet, jilin Hua Kang Shi yuan bioscience limited company, batch number 200201.
Reagent: superoxide dismutase (SOD) kit, malondialdehyde (MDA) kit, catalase (CAT) kit, glutathione peroxidase (GSH-Px) kit, reactive Oxygen Species (ROS) kit, and total antioxidant capacity (T-AOC) kit are all purchased from Nanjing's institute of biological engineering.
3. Experimental instrument
Illumination material: philips halogen lamp, blue interference filter (wavelength 450nm, transmittance 34%, half width 9nm, shanghai sea optical element factory), illuminometer (Shanghai photoelectric research institute), electronic thermometer, medical aluminum foil paper.
Illumination box: the self-made illumination box adopts a cubic sealed wooden box, the size is 1m multiplied by 1m, smooth diffuse reflection material aluminum foil paper is paved on the inner surface, and air outlets are arranged on two sides of the box. The temperature in the tank was set to 22-23℃and monitored with an electronic thermometer. The side of the illumination box is respectively provided with a small hole with the diameter of 2cm, the halogen lamp is used for transmitting the interference filter with the wavelength of 450nm, the light rays enter the illumination box through the small holes on the side, and the illumination intensity of the same horizontal plane monitored by the illuminometer is the same.
2. Experimental method
1. Grouping animals
Healthy SD rats, 80, were given natural lighting, and were fed adaptively for 5 days, and each group of rats was observed for general conditions and randomly and evenly divided into 8 groups according to body weight, which were a normal control group, a model group, a dosing group (examples 1-3, comparative examples 1-2), and a positive drug group, 10 animals each, and each animal in each group was labeled with picric acid colorant, respectively.
2. Establishment and administration of rat blue light injury induced asthenopia model
After 5d of adaptive feeding, healthy rats were randomized: normal control (no blue light), model (blue light), dosing group: examples 1-3, comparative examples 1-2 and positive drug groups.
The rats in the model group, the drug administration group and the positive drug group are subjected to dark adaptation for 36 hours before being subjected to experiments, are placed into an illumination box one by one, and are taken out after being continuously irradiated by blue light for 60 minutes. The normal control group was placed under indoor light. The model group, the administration group and the positive drug group were irradiated with blue light and fed for 3 months. The normal control group and the model group drink normally and drink normally. The administration group was administered by intragastric administration at a dose of 22.5mg/kg, and the positive administration group was administered by intragastric administration at a dose of 225 mg/kg. The rat body weight was recorded once a week, and the state of the rats was observed daily, in the morning and evening, and the feeding and drinking conditions.
3. Evaluation of rat eyesight
After the end of the administration, the rats were placed in the center of the white box and irradiated with 2700lux light for 300s, the behavior of the rats in the white box was recorded by photographing, and the time for the rats to stay in the white box was counted.
3. Detection of related antioxidant capacity in rat lens
At the expiration of the observation, animals were sacrificed, eyeballs were removed, and the lenses were peeled off from the eyeballs under a high power microscope, and the peeling process was performed on an ice tray. Adding the homogenate medium, homogenizing with a homogenizer, centrifuging at 4deg.C for 10min (12000 r/min), collecting supernatant, and determining GSH-Px and T-AOC of each group of rats according to the instruction of the kit.
4. Determination of SOD, GSH-Px, CAT Activity and ROS, MDA content in rat serum
Collecting eyeball, collecting venous blood around the eyeball, centrifuging at 3000rpm and 4deg.C for 10min, separating serum, and preserving at-20deg.C. And measuring SOD, GSH-Px, CAT activity, ROS and MDA content in serum according to the instruction of the kit.
5. Statistical treatment
All experimental results in this study(average) ±s (standard deviation); differences in significance of data between groups were single factor analysis of variance t-tested using SPSS statistical software. P (P)<0.05 shows statistical differences, P<0.01 shows a significant statistical difference.
3. Experimental results
1. Influence on the vision of rats irradiated with blue light
The results are shown in table 3, where the residence time in the white box was significantly longer for rats of the blue-irradiated model group than for normal control group (P < 0.01), indicating that blue irradiation resulted in vision impairment for rats of the model group. Compared with the model group, the retention time of rats in the administration group and the positive drug group in the white box is obviously shortened (P is less than 0.01 and P is less than 0.05), which shows that the administration group and the positive drug group have better protection effect on vision injury caused by blue light irradiation. The rats of the comparative example 1, the comparative example 2 and the positive drug group showed a significant increase in residence time in the white box (P < 0.05) compared to the example 3 group, indicating that the example 3 group had better protection against visual impairment caused by blue light irradiation than the comparative example 1, the comparative example 2 and the positive drug group.
TABLE 3 influence of test samples on vision of model rats
Note that: compared with the normal control group, the # P is less than 0.01; comparing with the model group, P <0.05, P < 0.01; ΔP <0.05 compared to example 3.
2. Detection of related antioxidant capacity in blue light irradiated rat lens
As shown in Table 4, the model rats had significantly lower oxidation resistance (P < 0.01) than the normal control group, as seen from both GSH-Px and T-AOC oxidation resistance indexes. Compared with the model group, the antioxidant value of rats in the administration group and the positive drug group is obviously increased (P is less than 0.01 and P is less than 0.05), which indicates that the administration group and the positive drug group have different degrees of antioxidant capacity on the lens of the rat with photodamage. Meanwhile, the rats of the comparative example 1 group, the comparative example 2 group and the positive drug group all have significantly reduced antioxidant values (P < 0.05) compared with the example 3 group, indicating that the example 3 group exhibits better antioxidant effect than the comparative example group and the positive drug group.
TABLE 4 influence of sample on model rat lens antioxidant index
Note that: compared with the normal control group, the # P is less than 0.01; comparing with the model group, P <0.05, P < 0.01; ΔP <0.05 compared to example 3.
3. Effect on oxidative stress levels in serum of blue-light-irradiated rats
As shown in table 5, the serum ROS and MDA levels were significantly higher in the model rats than in the normal control (P < 0.01), indicating high levels of oxidative stress in the blue-irradiated rats model. Compared with the model group, the ROS level and MDA content in the serum of rats in the administration group and the positive drug group are obviously reduced (P <0.01 and P < 0.05), which indicates that the administration group and the positive drug group can improve the oxidative stress state of the retina of the model rat and reduce the damage of reactive oxygen and various oxygen free radicals to the retina of the rat. The significant increase in ROS levels (P < 0.05) in the serum of rats in the comparative example 1, comparative example 2, and positive drug group compared to the example 3 group, indicates that the example 3 group has a better effect on reducing the level of oxidative stress than the comparative example 1, comparative example 2, and positive drug group.
TABLE 5 influence of sample on oxidative stress index in model rat serum
Note that: compared with the normal control group, the # P is less than 0.01; in comparison with the model group, # P <0.05, # P <0.01, and ΔP <0.05 in comparison with the example 3 group.
4. Effect on antioxidant stress kinase levels in vivo in blue light irradiated rat serum
As shown in table 6, the activity of SOD and GSH-PX in serum is significantly reduced (P < 0.01) compared with the normal control group, indicating that the level of antioxidant stress factor is reduced due to the higher level of oxidative damage in the rats in the model group. Meanwhile, CAT activity in serum of rats in the model group is obviously reduced (P < 0.01), which indicates that the rats in the model group have oxidative stress state in vivo and can cause stronger oxidative damage to retinal tissues of rats.
Compared with the model group, the administration group and the positive drug group can obviously improve the activities of SOD, GSH-Px and CAT in the serum of the rats irradiated by blue light (P <0.01 and P < 0.05), wherein compared with the group of the embodiment 3, the comparison example 1 group, the comparison example 2 group and the positive drug group show that the activities of SOD, GSH-Px and CAT in the serum of the rats are obviously reduced (P < 0.05), the administration group and the positive drug group can improve the activities of antioxidant enzymes in the serum of the rats irradiated by blue light, and play an antioxidant role, thereby improving the oxidative stress state of retina and resisting damage caused by irradiation of visual function blue light, and the effect of the group of the embodiment 3 is superior to that of the comparison example 1 group, the comparison example 2 group and the positive drug group.
TABLE 6 influence of samples on in vivo antioxidant stress kinase Activity in model rat serum
Note that: compared with the normal control group, the # P is less than 0.01; in comparison with the model group, # P <0.05, # P <0.01, and ΔP <0.05 in comparison with the example 3 group.
The experimental result shows that the composition provided by the invention has obvious effect of resisting visual function injury caused by blue light irradiation. The composition can prevent vision deterioration caused by blue light irradiation of rats, improve the oxidation resistance level of crystalline lenses, and increase the whole oxidation resistance of animals, and shows that the composition can effectively reduce the most main pathological link of high oxidation stress level, which causes blue light damage of visual functions, thereby protecting the visual functions of animals from damage. Particularly, the composition is suitable for long-term use, and has the effects of resisting damage caused by blue light irradiation, relieving visual fatigue and protecting eyesight.
The invention has been further described above in connection with specific embodiments, which are exemplary only and do not limit the scope of the invention in any way. It will be understood by those skilled in the art that various changes and substitutions of details and forms of the technical solution of the present invention may be made without departing from the spirit and scope of the present invention, but these changes and substitutions fall within the scope of the present invention.
Claims (8)
1. The composition for resisting asthenopia caused by blue light irradiation is characterized by comprising the following active components in parts by weight: 8-12 parts of medlar polysaccharide, 0.1-0.6 part of catechin, 0.2-1 part of myricetin, 0.4-1.5 part of luteolin, 1-2.5 parts of chlorogenic acid, 20-40 parts of ophiopogon polysaccharide, 0.02-0.08 part of ophiopogon saponin D, 0.01-0.05 part of ophiopogon methyl flavanone A, 5-13 parts of paeoniflorin, 0.2-0.8 part of gallic acid methyl ester, 1.8-3.6 parts of paeoniflorin and 80-120 parts of zinc gluconate.
2. Composition according to claim 1, characterized in that it consists of the following active ingredients in parts by weight: 9-11 parts of medlar polysaccharide, 0.2-0.5 part of catechin, 0.4-0.8 part of myricetin, 0.5-1.0 part of luteolin, 1.2-2.0 parts of chlorogenic acid, 22-38 parts of ophiopogon polysaccharide, 0.03-0.07 part of ophiopogon saponin D, 0.02-0.04 part of ophiopogon methyl flavanone A, 6-10 parts of paeoniflorin, 0.3-0.7 part of gallic acid methyl ester, 2.0-3.5 parts of paeoniflorin and 80-120 parts of zinc gluconate.
3. Composition according to claim 2, characterized in that it consists of the following active ingredients in parts by weight: 10 parts of medlar polysaccharide, 0.3 part of catechin, 0.6 part of myricetin, 0.7 part of luteolin, 1.5 parts of chlorogenic acid, 30 parts of ophiopogon polysaccharide, 0.04 part of ophiopogon saponin D, 0.04 part of ophiopogon methyl flavanone A, 9.5 parts of paeoniflorin, 0.5 part of gallic acid methyl ester, 2.6 parts of paeoniflorin and 100 parts of zinc gluconate.
4. A process for the preparation of a composition as claimed in any one of claims 1 to 3, comprising the steps of: mixing the wolfberry polysaccharide, catechin, myricetin, luteolin, chlorogenic acid, ophiopogon polysaccharide, ophiopogon saponin D, ophiopogon methyl flavanone A, paeoniflorin, methyl gallate, paeoniflorin and zinc gluconate according to the formula amount, and sieving to obtain the composition.
5. The method of claim 4, wherein the sieving is through a 60-120 mesh sieve.
6. Use of a composition according to any one of claims 1-3 or a composition according to any one of claims 4-5 in the manufacture of a medicament for combating asthenopia caused by blue light irradiation.
7. A pharmaceutical product for combating asthenopia caused by blue light irradiation, characterized by comprising a composition according to any one of claims 1-3.
8. The pharmaceutical product of claim 7, wherein the pharmaceutical product is a tablet, capsule, granule, suspension, powder or pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311598876.6A CN117298142B (en) | 2023-11-28 | 2023-11-28 | Composition for resisting asthenopia and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311598876.6A CN117298142B (en) | 2023-11-28 | 2023-11-28 | Composition for resisting asthenopia and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117298142A CN117298142A (en) | 2023-12-29 |
| CN117298142B true CN117298142B (en) | 2024-01-30 |
Family
ID=89281433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311598876.6A Active CN117298142B (en) | 2023-11-28 | 2023-11-28 | Composition for resisting asthenopia and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117298142B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104383257A (en) * | 2014-12-04 | 2015-03-04 | 邹士东 | Chinese medicinal preparation for treating xerophthalmia due to liver depression and deficiency of yin |
| CN108261472A (en) * | 2018-02-11 | 2018-07-10 | 成都图径生物科技有限公司 | Composition for relieving asthenopia containing matrimony vine, chrysanthemum, γ-aminobutyric acid and theanine |
| CN109908234A (en) * | 2019-04-19 | 2019-06-21 | 中泰宜佳健康科技（北京）有限责任公司 | One kind is for composition for relieving asthenopia and its preparation and preparation method |
-
2023
- 2023-11-28 CN CN202311598876.6A patent/CN117298142B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104383257A (en) * | 2014-12-04 | 2015-03-04 | 邹士东 | Chinese medicinal preparation for treating xerophthalmia due to liver depression and deficiency of yin |
| CN108261472A (en) * | 2018-02-11 | 2018-07-10 | 成都图径生物科技有限公司 | Composition for relieving asthenopia containing matrimony vine, chrysanthemum, γ-aminobutyric acid and theanine |
| CN109908234A (en) * | 2019-04-19 | 2019-06-21 | 中泰宜佳健康科技（北京）有限责任公司 | One kind is for composition for relieving asthenopia and its preparation and preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 清肝养阴汤熏蒸联合玻璃酸钠滴眼液治疗干眼症129例;王朝霞;韦春玲;左海霞;王晓月;;陕西中医;-(03);全文 * |
| 缓解视疲劳功能中药复方保健产品配方规律及特点分析;周雪;张建军;乐娜;刘金莲;刘晔斌;王淳;王林元;陈亮;阚君陶;;中草药(14);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117298142A (en) | 2023-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109091675B (en) | Compound low-concentration atropine medicine eye drops and preparation method thereof | |
| ES2710750T3 (en) | Composition used to improve the density of macular pigment in the eyes and prevent or treat age-related macular degeneration | |
| CN103977157A (en) | Lycium ruthenicum eyesight-improving eye-protecting tea | |
| CN102362924A (en) | Medicinal composition for treating ophthalmic diseases and preparation method thereof | |
| CN111821355A (en) | Eyesight-protecting lycium ruthenicum and lutein chewable tablet and preparation method thereof | |
| CN105106286A (en) | Health product with effects of protecting eyes and improving eyesight | |
| CN117298142B (en) | Composition for resisting asthenopia and preparation method and application thereof | |
| CN115444134A (en) | Blueberry lutein ester chewable tablet and preparation method thereof | |
| CN102940753B (en) | Pills for treating glaucoma and preparation method | |
| CN106344827A (en) | Eye drops for treating presbyopia and preparation method of eye drops | |
| CN111513157A (en) | Health tea containing medlar and cassia seed and preparation method thereof | |
| KR101241455B1 (en) | Bean curd having hypotensive effect | |
| CN104606571A (en) | Fresh spinach root tea substituted drink with effects of helping produce saliva and slaking thirst and preparation method thereof | |
| CN114272305B (en) | Visual fatigue resistant herbal tea and preparation method thereof | |
| CN104523981A (en) | Traditional Chinese medicine preparation for treating optic neuritis and preparation method | |
| US20240050504A1 (en) | Traditional chinese medicine eye drops and the preparation method thereof | |
| JPS61239855A (en) | Food for improving physical constitution | |
| CN106491730A (en) | A kind of treat Chinese medicine composition of glaucoma and preparation method thereof | |
| US20130011502A1 (en) | Composition for a dietary supplement for the treatment of hemorrhoids | |
| CN113208016A (en) | Preparation method of berry compound beverage for relieving asthenopia | |
| CN114288347A (en) | Medicine and food composition for benefiting eyesight and improving eyesight and preparation method and application method thereof | |
| CN113384653A (en) | Traditional Chinese medicine composition for preventing and treating hypopsia, preparation and preparation method | |
| Urokovich | PROPERTIES OF HYPOTENSIVE PLANTS GROWING IN UZBEKISTAN | |
| CN115251217A (en) | Visual fatigue relieving tabletting candy as well as preparation method and application thereof | |
| CN114886985A (en) | Traditional Chinese medicine preparation for nourishing liver, improving eyesight and resisting asthenopia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |